Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation.

Publication date: Feb 06, 2024

For psoriatic patients who need to receive non-live or live vaccines, evidence-based recommendations are needed regarding whether to pause or continue systemic therapies for psoriasis and/or psoriatic arthritis. To evaluate literature regarding vaccine efficacy and safety and to generate consensus-based recommendations for adults receiving systemic therapies for psoriasis and/or psoriatic arthritis receiving non-live or live vaccines. Using a modified Delphi process, 22 consensus statements were developed by the National Psoriasis Foundation Medical Board and COVID-19 Task Force, and infectious disease experts. Key recommendations include continuing most oral and biologic therapies without modification for patients receiving non-live vaccines; consider interruption of methotrexate for non-live vaccines. For patients receiving live vaccines, discontinue most oral and biologic medications before and after administration of live vaccine. Specific recommendations include discontinuing most biologic therapies, except for abatacept, for 2-3 half-lives before live vaccine administration and deferring next dose 2-4 weeks after live vaccination. Studies regarding infection rates after vaccination are lacking. Interruption of anti-psoriatic oral and biologic therapies is generally not necessary for patients receiving non-live vaccines. Temporary interruption of oral and biologic therapies before and after administration of live vaccines is recommended in most cases.

Concepts Keywords
Arthritis abatacept
Biologics acitretin
Experts adalimumab
Methotrexate apremilast
Vaccination biologics
brodalumab
certolizumab
cyclosporine
deucravacitinib
etanercept
golimumab
guselkumab
infliximab
ixekizumab
methotrexate
psoriasis
psoriatic arthritis
recommendation
risankizumab
secukinumab
tildrakizumab
tofacitinib
ustekinumab
vaccination
vaccines

Semantics

Type Source Name
disease VO vaccination
disease MESH Psoriasis
disease MESH Psoriatic Arthritis
disease VO vaccine efficacy
disease IDO process
disease MESH COVID-19
disease MESH infectious disease
pathway REACTOME Infectious disease
drug DRUGBANK Methotrexate
disease VO vaccine
drug DRUGBANK Abatacept
disease VO dose
disease MESH infection
drug DRUGBANK Acitretin
drug DRUGBANK Adalimumab
drug DRUGBANK Apremilast
drug DRUGBANK Brodalumab
drug DRUGBANK Ciclosporin
drug DRUGBANK Etanercept
drug DRUGBANK Golimumab
drug DRUGBANK Guselkumab
drug DRUGBANK Infliximab
drug DRUGBANK Ixekizumab
drug DRUGBANK Secukinumab
drug DRUGBANK Tildrakizumab
drug DRUGBANK Tofacitinib
drug DRUGBANK Ustekinumab

Original Article

(Visited 1 times, 1 visits today)